Truist Financial downgraded Insulet from Buy to Hold following a revised, softer sales forecast for its Omnipod insulin pumps, especially in the U.S. This downgrade caused Insulet's stock to drop to $133.26, though the new price target of $153 still suggests nearly 15% upside. Despite the cautious outlook, Insulet posted strong Q2 results with revenue up 23.5% to $801.7 million and adjusted EPS rising 41.5% to $1.66, driven by robust international growth. Investors are weighing the company's strong recent performance against concerns over slower U.S. sales growth in the second half of the year.
On September 21, 2026, Sandisk was added to the S&P 100 index, replacing Nike, which was removed on the same day. This change reflects shifts in market capitalization and company performance within the index. The update is significant for investors t...
Several top analysts, including Cantor Fitzgerald, Guggenheim, Morgan Stanley, and BTIG Research, have raised price targets and upgraded their outlooks for ServiceNow, signaling confidence in the company's long-term growth. Despite this, the stock ha...
Piper Sandler lowered Colgate-Palmolive's price target to $95 due to weak North American demand and rising competition. The company is responding by focusing on premium oral care innovations, expanding the Fabuloso line, increasing advertising, and c...
MillerKnoll is set to report Q3 2026 earnings with analysts expecting $0.35 EPS and $940.93 million in revenue. The North America Contract segment shows strength with higher prices and volumes, while the Global Retail segment struggles due to tariffs...
Rothschild & Co Redburn raised Microsoft's price target from $400 to $440 following strong fiscal 2026 results, with revenue up 18% to $331.8 billion and net income rising 31% to $133.7 billion, driven by cloud and AI demand. Despite the target hike,...
